المؤلفون: DiNardo CD; Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX., Venugopal S; Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX., Lachowiez C; Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX., Takahashi K; Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX., Loghavi S; Department of Hematopathology, University of Texas MD Anderson Cancer Center, Houston, TX., Montalban-Bravo G; Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX., Wang X; Department of Biostatistics, University of Texas MD Anderson Cancer Center, Houston, TX., Carraway H; Leukemia Program, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH., Sekeres M; Division of Hematology, Sylvester Cancer Center, University of Miami, Miami, FL., Sukkur A; Weill Cornell Medical College, The New York Presbyterian Hospital, New York, NY., Hammond D; Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX., Chien K; Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX., Maiti A; Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX., Masarova L; Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX., Sasaki K; Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX., Alvarado Y; Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX., Kadia T; Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX., Short NJ; Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX., Daver N; Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX., Borthakur G; Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX., Ravandi F; Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX., Kantarjian HM; Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX., Patel B; Leukemia Program, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH., Dezern A; Division of Hematologic Malignancies and Bone Marrow Transplantation, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD., Roboz G; Weill Cornell Medical College, The New York Presbyterian Hospital, New York, NY., Garcia-Manero G; Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX.

المصدر: Blood advances [Blood Adv] 2023 Jun 13; Vol. 7 (11), pp. 2378-2387.

نوع المنشور: Multicenter Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: American Society of Hematology Country of Publication: United States NLM ID: 101698425 Publication Model: Print Cited Medium: Internet ISSN: 2473-9537 (Electronic) Linking ISSN: 24739529 NLM ISO Abbreviation: Blood Adv Subsets: MEDLINE

مواضيع طبية MeSH: Isocitrate Dehydrogenase*/genetics , Myelodysplastic Syndromes*/drug therapy , Myelodysplastic Syndromes*/genetics, Humans ; Aged ; Mutation ; Azacitidine/adverse effects

المؤلفون: Lachowiez CA; Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Reville PK; Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Kantarjian H; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Jabbour E; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Borthakur G; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Daver N; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Issa G; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Furudate K; Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Tanaka T; Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Pierce S; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Tang G; Department of hematopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Patel KP; Department of hematopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Medeiros J; Department of hematopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Abbas HA; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Haddad F; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Hammond D; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Short NJ; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Maiti A; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Yilmaz M; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Sasaki K; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Takahashi K; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Pemmaraju N; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Konopleva M; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Garcia-Manero G; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Ravandi F; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Kadia TM; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Loghavi S; Department of hematopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., DiNardo CD; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

المصدر: American journal of hematology [Am J Hematol] 2022 Nov; Vol. 97 (11), pp. 1443-1452. Date of Electronic Publication: 2022 Sep 15.

نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Wiley-Blackwell Country of Publication: United States NLM ID: 7610369 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1096-8652 (Electronic) Linking ISSN: 03618609 NLM ISO Abbreviation: Am J Hematol Subsets: MEDLINE

مواضيع طبية MeSH: Isocitrate Dehydrogenase*/genetics , Leukemia, Myeloid, Acute*/drug therapy , Leukemia, Myeloid, Acute*/genetics, Bridged Bicyclo Compounds, Heterocyclic ; Cohort Studies ; Humans ; Mutation ; Nucleophosmin ; Prognosis ; Retrospective Studies ; Sulfonamides

المؤلفون: Venugopal S; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Takahashi K; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Daver N; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Maiti A; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Borthakur G; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Loghavi S; Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Short NJ; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Ohanian M; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Masarova L; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Issa G; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Wang X; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Carlos BR; Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Yilmaz M; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Kadia T; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Andreeff M; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Ravandi F; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Konopleva M; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Kantarjian HM; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., DiNardo CD; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. cdinardo@mdanderson.org.

المصدر: Blood cancer journal [Blood Cancer J] 2022 Jan 25; Vol. 12 (1), pp. 10. Date of Electronic Publication: 2022 Jan 25.

نوع المنشور: Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Nature Pub. Group Country of Publication: United States NLM ID: 101568469 Publication Model: Electronic Cited Medium: Internet ISSN: 2044-5385 (Electronic) Linking ISSN: 20445385 NLM ISO Abbreviation: Blood Cancer J Subsets: MEDLINE

مواضيع طبية MeSH: Aminopyridines/*therapeutic use , Antineoplastic Combined Chemotherapy Protocols/*therapeutic use , Azacitidine/*therapeutic use , Isocitrate Dehydrogenase/*genetics , Leukemia, Myeloid, Acute/*drug therapy , Triazines/*therapeutic use, Adult ; Aged ; Aged, 80 and over ; Aminopyridines/adverse effects ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Azacitidine/adverse effects ; Female ; Humans ; Leukemia, Myeloid, Acute/genetics ; Male ; Middle Aged ; Mutation/drug effects ; Treatment Outcome ; Triazines/adverse effects ; Young Adult

المؤلفون: Venugopal S; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas., Maiti A; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas., DiNardo CD; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas., Loghavi S; Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Daver NG; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas., Kadia TM; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas., Rausch CR; Division of Pharmacy, The University of Texas MD Anderson Cancer Center, Houston, Texas., Alvarado Y; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas., Ohanian M; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas., Sasaki K; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas., Short NJ; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas., Takahashi K; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas., Yilmaz M; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas., Ravandi F; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas., Kantarjian HM; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas., Konopleva MY; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.

المصدر: American journal of hematology [Am J Hematol] 2021 May 01; Vol. 96 (5), pp. E154-E157. Date of Electronic Publication: 2021 Feb 19.

نوع المنشور: Clinical Trial, Phase II; Comparative Study; Letter; Research Support, N.I.H., Extramural

بيانات الدورية: Publisher: Wiley-Blackwell Country of Publication: United States NLM ID: 7610369 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1096-8652 (Electronic) Linking ISSN: 03618609 NLM ISO Abbreviation: Am J Hematol Subsets: MEDLINE

مواضيع طبية MeSH: Antineoplastic Combined Chemotherapy Protocols/*therapeutic use , Isocitrate Dehydrogenase/*genetics , Leukemia, Myeloid, Acute/*drug therapy , Neoplasm Proteins/*genetics, Adult ; Aged ; Aged, 80 and over ; Bridged Bicyclo Compounds, Heterocyclic/administration & dosage ; Decitabine/administration & dosage ; Female ; Follow-Up Studies ; Humans ; Kaplan-Meier Estimate ; Leukemia, Myeloid, Acute/genetics ; Male ; Middle Aged ; Mutation ; Neoplasms, Second Primary/drug therapy ; Neoplasms, Second Primary/genetics ; Salvage Therapy ; Sulfonamides/administration & dosage